← All trials
NCT05035680
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 14, 2022
- Primary completion
- Nov 25, 2022
- Completion date
- Apr 25, 2023
- First posted
- Sep 5, 2021
- Last posted
- Sep 5, 2021
- Enrollment
- 173
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Bill and Melinda Gates FoundationLead sponsor
- IQVIACollaborator
- Bill and Melinda Gates FoundationStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.